Publication
» Go to news mainIncidence of pancreatic cancer during long‑term follow‑up in patients with incidental pancreatic cysts smaller than 2 cm
A new publication from Dr. Mathew Bligh!
Click here to view the article.
Abstract
Purpose
To assess the long-term malignancy risk of incidental small pancreatic cysts.
Materials and methods
In this HIPAA-compliant, IRB-approved, retrospective, multi-institutional study, the long-term incidence of pancreatic cancer was compared between patients with and without small pancreatic cysts. Patients with incidental pancreatic cysts ≥ 0.5 and < 2.0 cm in maximal diameter, detected on MRI performed between 1999 and 2011, represented the “small pancreatic cyst” group. Patients that underwent MRI between 2005 and 2011 and had no reported pancreatic cysts represented the comparison “no cyst” group.
Results
The “small pancreatic cyst” group included 267 patients, ages 63.4 ± 11.8 years, 166/267 (62%) women with a mean follow-up of 8.6 ± 4.3 years, median 9.2 years; the “no cyst” group included 1,459 patients, ages 64.6 ± 12 years, 794/1,459 (54%) women with a mean follow-up of 7.0 ± 4.2 years, median 7.8 (p values 0.12, 0.02, < 0.001, respectively). Two/267 (0.7%) patients developed pancreatic cancer at a separate location from the known cyst in the “small pancreatic cyst” group, with a cancer rate of 0.9 (95% CI 0.1–3.1) cases per 1,000 patient-years. In the “no cyst” cohort, 18/1,459 (1.2%) patients developed pancreatic cancer, with a cancer rate of 1.8 (95% CI 1.2–3.1) cases per 1,000 patient-years (p = 0.6). The all-cause mortality was similar in both groups: 57/267 (21%) vs. 384/1,459 (26%) (p = 0.09).
Conclusion
The long-term risk of pancreatic malignancy in asymptomatic patients with incidental pancreatic cysts less than 2 cm is 0.9 cases per 1,000 patient-years of follow-up, similar to those without pancreatic cysts. These very few pancreatic cancers developed at a separate location from the known cyst.
Recent News
- ‘A paradigm shift': A first in Canada, donor‑funded nuclear medicine scanner is helping QEII physicians assess and diagnose diseases with precision that wasn’t previously possible — all while tackling waitlists with greater efficiency
- New interventional radiology suite and hybrid operating room at the Halifax Infirmary
- Nova Scotia gets first‑in‑Canada relocatable MRI
- QEII welcomes the first GE StarGuide SPECT‑CT scanner in Canada.
- The first 68Ga‑PSMA PET scans in Atlantic Canada mark a new era in prostate cancer assessment
- Dr. David Volders awarded the Dr. Charles Lo Prize in Radiology Research
- Radiology Research Day 2024
- Program Administrator Award of Excellence